A Multi-Centered Randomized Phase II Comparison of Single-Agent Carboplatin versus the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer

ID Number 15-1075

Principal Investigator(s)
Amy Tiersten

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared to the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer (TNBC)

Contact Information
Joni Gomes
(212) 824-7309

Recruiting Patients: Yes